Assessment of cardiovascular risk in patient with ankyslosing spondylitis using the SCORE2 risk algorithm
Main Article Content
Abstract
Ankylosing spondylitis (AS), a chronic inflammatory rheumatic disease, is a subtype of axial spondyloarthritis disorders. The disease affects the joints, spine, and extra-articular organs. Patients with AS have an increased cardiovascular risk due to the combined effects of systemic inflammation and traditional cardiovascular risk factors. Assessment of cardiovascular risk in patients with AS will optimize risk factor management and improve disease prognosis. This study was conducted on 69 patients with ankylosing spondylitis at the Rheumatology Center of Bach Mai Hospital from August 2024 to July 2025. Among the participants, 44.9% had low-to-moderate cardiovascular risk, 40.6% had high cardiovascular risk, and 14.5% had very high cardiovascular risk. The 10-year cardiovascular risk in patients with AS was associated with age, disease activity, disease duration, gender and CRP-hs level. As such, cardiovascular risk assessment should be routinely performed in patients with ankylosing spondylitis.
Article Details
Keywords
Cardiovascular risk, ankylosing spondylitis, SCORE-2
References
2. Mok CC, Kwok CL, Ho LY, Chan PT, Yip SF. Life expectancy, standardized mortality ratios, and causes of death in six rheumatic diseases in Hong Kong, China. Arthritis Rheum. 2011;63(5):1182-1189. doi:10.1002/art.30277
3. Agca R, Heslinga SC, Rollefstad S, et al. EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015/2016 update. Ann Rheum Dis. 2017;76(1):17-28. doi:10.1136/annrheumdis-2016-209775
4. Colantonio LD, Bittner V. Cardiovascular Risk Prediction in Older Adults. Curr Atheroscler Rep. 2025;27(1):88. doi:10.1007/s11883-025-01339-2
5. Visseren FLJ, Mach F, Smulders YM, et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice: Developed by the Task Force for cardiovascular disease prevention in clinical practice with representatives of the European Society of Cardiology and 12 medical societies With the special contribution of the European Association of Preventive Cardiology (EAPC). Eur Heart J. 2021;42(34):3227-3337. doi:10.1093/eurheartj/ehab484
6. Haroon NN, Paterson JM, Li P, Inman RD, Haroon N. Patients With Ankylosing Spondylitis Have Increased Cardiovascular and Cerebrovascular Mortality: A Population-Based Study. Ann Intern Med. 2015;163(6):409-416. doi:10.7326/M14-2470
7. Sarp Ü, ÜstÜner E, Kutlay S, Ataman Ş, Kutlay S. Biomarkers of Cardiovascular Disease in Patients With Ankylosing Spondylitis. Arch Rheumatol. 2020;35(3):435-439. doi:10.46497/ArchRheumatol.2020.7868
8. Klisic A, Kotur-Stevuljevic J, Cure O, et al. Cardiovascular Risk in Patients with Ankylosing Spondylitis. J Clin Med. 2024;13(20):6064. doi:10.3390/jcm13206064
9. Navarini L, Currado D, Marino A, et al. Persistence of C-reactive protein increased levels and high disease activity are predictors of cardiovascular disease in patients with axial spondyloarthritis. Sci Rep. 2022;12(1):7498. doi:10.1038/s41598-022-11640-8